📊 EUDAW Key Takeaways
Is EUDAW a Good Investment? Thesis Analysis
EUDA Health faces severe financial distress with negative stockholders' equity of -$6.0M, indicating liabilities exceed assets. The company is unprofitable with a -6.0% net margin and negative free cash flow of -$488K, while generating minimal gross profit (1.0% margin) on $40.1M in revenue, suggesting fundamental operational inefficiencies.
Why Buy EUDAW? Key Strengths
- Positive revenue base of $40.1M provides foundation for operations
- No significant long-term debt burden disclosed
- Cash position of $837.3K provides short-term liquidity runway
EUDAW Investment Risks to Consider
- Negative stockholders' equity (-$6.0M) indicates technical insolvency and high bankruptcy risk
- Severely negative cash flow generation (-$469.9K operating cash flow) is unsustainable without external funding
- Extremely low gross margin (1.0%) suggests pricing power issues, cost structure problems, or inability to scale profitably
- Current ratio of 0.79x indicates insufficient current assets to cover near-term obligations
- Negative operating margin (-4.9%) demonstrates core business is unprofitable before financing costs
Key Metrics to Watch
- Gross margin expansion and path to profitability
- Operating cash flow trend and cash burn rate
- Ability to reduce debt/liabilities and restore positive equity
EUDAW Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
EUDAW Profitability Ratios
EUDAW vs Default Sector
How EUDA Health Holdings Ltd compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is EUDAW Overvalued or Undervalued?
Based on fundamental analysis, EUDA Health Holdings Ltd has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
EUDAW Balance Sheet & Liquidity
EUDAW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: EUDA Health Holdings Ltd's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.09 reflects profitable operations.
EUDAW Growth Metrics (YoY)
EUDAW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2023 | $1.7M | $218.8K | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
EUDAW Capital Allocation
EUDAW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for EUDA Health Holdings Ltd (CIK: 0001847846)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EUDAW
What is the AI rating for EUDAW?
EUDA Health Holdings Ltd (EUDAW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are EUDAW's key strengths?
Claude: Positive revenue base of $40.1M provides foundation for operations. No significant long-term debt burden disclosed.
What are the risks of investing in EUDAW?
Claude: Negative stockholders' equity (-$6.0M) indicates technical insolvency and high bankruptcy risk. Severely negative cash flow generation (-$469.9K operating cash flow) is unsustainable without external funding.
What is EUDAW's revenue and growth?
EUDA Health Holdings Ltd reported revenue of $40.1M.
Does EUDAW pay dividends?
EUDA Health Holdings Ltd does not currently pay dividends.
Where can I find EUDAW SEC filings?
Official SEC filings for EUDA Health Holdings Ltd (CIK: 0001847846) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EUDAW's EPS?
EUDA Health Holdings Ltd has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EUDAW a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, EUDA Health Holdings Ltd has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EUDAW stock overvalued or undervalued?
Valuation metrics for EUDAW: ROE of N/A (sector avg: 15%), net margin of -6.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EUDAW stock in 2026?
Our dual AI analysis gives EUDA Health Holdings Ltd a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EUDAW's free cash flow?
EUDA Health Holdings Ltd's operating cash flow is $-469.9K, with capital expenditures of $18.1K. FCF margin is -1.2%.
How does EUDAW compare to other Default stocks?
Vs Default sector averages: Net margin -6.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.79 (avg: 1.8).